Javier Afonso (@afonsera1) 's Twitter Profile
Javier Afonso

@afonsera1

Oncólogo médico con especial interés en tumores genitourinarios./ Medical oncologist with special interest in genitourinary tumors.

ID: 111417805

calendar_today04-02-2010 21:23:51

1,1K Tweet

1,1K Followers

2,2K Following

Tom Powles (@tompowles1) 's Twitter Profile Photo

The FDA approval of EV + Pembro in cisplatin ineligible muscle invasive bladder is based on pCR=57% & OS HR of 0.5 vs cystectomy alone. Initial systemic therapy rather than surgery is now preferable for all eligible pts. I suspect this is not the last we hear from EVP in MIBC.

The FDA approval of EV + Pembro in cisplatin ineligible muscle invasive bladder is based on pCR=57% &  OS HR of 0.5 vs cystectomy alone. Initial systemic therapy rather than surgery is now preferable for all eligible pts. I suspect this is not the last we hear from EVP in MIBC.
Enrique Grande (@drenriquegrande) 's Twitter Profile Photo

⚡️ Hyper-progression with Nivolumab + Ipilimumab in RMC Phase II data in renal medullary carcinoma show rapid progression in all treated patients, with half meeting criteria for hyper-progression. Single-cell analyses indicate an IFN-γ–driven “myeloid mimicry” program in

⚡️ Hyper-progression with Nivolumab + Ipilimumab in RMC

Phase II data in renal medullary carcinoma show rapid progression in all treated patients, with half meeting criteria for hyper-progression. Single-cell analyses indicate an IFN-γ–driven “myeloid mimicry” program in
Daniel Castellano (@cdanicas) 's Twitter Profile Photo

🎯🎯.- How to apply the current evidence in the treatment of mCSPC!! Excellent review.🙌 nature.com/articles/s4157… 👉.- The new molecular precision "triplet intensification" is here. 👉.- A HRR (BRCA2+) alt and pTEN loss population have a poor prognosis. 👉.- We need to better

🎯🎯.- How to apply the current evidence in the treatment of mCSPC!! Excellent review.🙌
nature.com/articles/s4157…

👉.- The new molecular precision "triplet intensification" is here.
👉.- A HRR (BRCA2+) alt and pTEN loss population have a poor prognosis.
👉.- We need to better
Javier Afonso (@afonsera1) 's Twitter Profile Photo

Longer is better? It seems that it's not always: Optimal Duration of Androgen Deprivation Therapy With Definitive Radiotherapy for Localized Prostate Cancer jamanetwork.com/journals/jamao…

Advanced Prostate Cancer Consensus Conference (@apccc_lugano) 's Twitter Profile Photo

Dear Colleagues at #PROSCA25 As we approach #APCCC26 NEXT YEAR we share our Publication from last APCCC Management of patients with Advanced #ProstateCancer : A Report from #APCCC24 LINK TO ARTICLE👇 sciencedirect.com/science/articl… The Advanced Prostate Cancer Consensus

Dear Colleagues at #PROSCA25
As we approach #APCCC26 NEXT YEAR we share our Publication from last APCCC

Management of patients with Advanced #ProstateCancer : A Report from #APCCC24  

 LINK TO ARTICLE👇 sciencedirect.com/science/articl…     

The Advanced Prostate Cancer Consensus
Tom Powles (@tompowles1) 's Twitter Profile Photo

What’s the future of muscle invasive bladder cancer #SimposioSOGUG25 Pathological CR rates of 57% for EVP points towards cystectomy being delayed until maximum EVP effectiveness. Also fewer patients will have cystectomy. Studies are needed to ensure this approach is safe.

What’s the future of muscle invasive bladder cancer #SimposioSOGUG25
Pathological CR rates of 57% for EVP points towards cystectomy being delayed until maximum EVP effectiveness. Also fewer patients will have cystectomy. Studies are needed to ensure this approach is safe.
Rishabh Jain (@drrishabhonco) 's Twitter Profile Photo

Doublet vs Triplet in mHSPC: Fast Takeaways 🔍 #GlobalForum25 #PROSCA25 🧬 ADT + ARPI = SOC Intensify only when biology or volume demands it. 💥 Doublet enough 😊 Metachronous low volume 😊 Elderly low volume 😊 Low risk biology 👉 ADT + ARPI 🔥 Biology driven intensification

Doublet vs Triplet in mHSPC: Fast Takeaways 🔍
#GlobalForum25 #PROSCA25 

🧬 ADT + ARPI = SOC
Intensify only when biology or volume demands it.

💥 Doublet enough
😊 Metachronous low volume
😊 Elderly low volume
😊 Low risk biology
👉 ADT + ARPI

🔥 Biology driven intensification
Rishabh Jain (@drrishabhonco) 's Twitter Profile Photo

ARPI interactions you must remember in clinic. Apalutamide and Enzalutamide cause most avoid signals while Darolutamide stays the safest ⚠️💊 Bookmark this for quick recall 🔖 OncoAlert ASCO ESMO - Eur. Oncology ESMO Open #OncoTwitter #MedTwitter #ProstateCancer #DDIs #GlobalForum25

ARPI interactions you must remember in clinic. 
Apalutamide and Enzalutamide cause most avoid signals while Darolutamide stays the safest ⚠️💊
Bookmark this for quick recall 🔖

<a href="/oncoalert/">OncoAlert</a> <a href="/asco/">ASCO</a> <a href="/myesmo/">ESMO - Eur. Oncology</a> <a href="/esmo_open/">ESMO Open</a>
#OncoTwitter #MedTwitter #ProstateCancer #DDIs #GlobalForum25
Rishabh Jain (@drrishabhonco) 's Twitter Profile Photo

Prostate Cancer Genetics 🧬🔥 What drives advanced mCRPC? #GlobalForum25 #PROSCA25 AR pathway dominates, PTEN loss and PI3K-AKT next, then DDR defects, Rb loss, and TP53 mutations. These are the major therapeutic and prognostic signals. And the ARPi + PARPi story is crystal

Prostate Cancer Genetics 🧬🔥
What drives advanced mCRPC?
#GlobalForum25 #PROSCA25 

AR pathway dominates, PTEN loss and PI3K-AKT next, then DDR defects, Rb loss, and TP53 mutations. These are the major therapeutic and prognostic signals.

And the ARPi + PARPi story is crystal
Rishabh Jain (@drrishabhonco) 's Twitter Profile Photo

Before ordering HRR testing, ask this: which method will actually find the mutation? #GlobalForum25 #PROSCA25 🩸 Germline Easy access, stable panels, picks up only 20-50 percent of HRR mutations. Most variants inherited >80 percent. gBRCA2 yield about 2-3.5 percent. 🧫 Somatic

Before ordering HRR testing, ask this: which method will actually find the mutation? 
#GlobalForum25 #PROSCA25

🩸 Germline
Easy access, stable panels, picks up only 20-50 percent of HRR mutations.
Most variants inherited &gt;80 percent.
gBRCA2 yield about 2-3.5 percent.

🧫 Somatic
Jame Abraham, MD, FACP (@jamecancerdoc) 's Twitter Profile Photo

Physical activity decreases cancer burden by alleviating immunosenescence-related inflammation and improving overall immunity x.com/erictopol/stat… ⁦OncoAlert

Physical activity decreases cancer burden by alleviating immunosenescence-related inflammation and improving overall immunity x.com/erictopol/stat… ⁦<a href="/OncoAlert/">OncoAlert</a>⁩
Advanced Prostate Cancer Consensus Conference (@apccc_lugano) 's Twitter Profile Photo

Comparison of prostate-specific antigen kinetics between androgen receptor signaling inhibitor doublet therapy and androgen receptor signaling inhibitor with docetaxel triplet therapy in patients with metastatic castration-sensitive #ProstateCancer sciencedirect.com/science/articl…

Comparison of prostate-specific antigen kinetics between androgen receptor signaling inhibitor doublet therapy and androgen receptor signaling inhibitor with docetaxel triplet therapy in patients with metastatic castration-sensitive #ProstateCancer

sciencedirect.com/science/articl…
Lucia Etxebarria (@laetxebarria) 's Twitter Profile Photo

Los medios están perdiendo interés en Irán. Los políticos están perdiendo interés en Irán. Las celebridades y los influencers nunca han mostrado interés por Irán . No lo permitamos. 90 millones de iraníes sufren la mayor matanza del siglo y están aislados del mundo. ¡Sé su voz!

Los medios están perdiendo interés en Irán. Los políticos están perdiendo interés en Irán. Las celebridades y los influencers nunca han mostrado interés por Irán . No lo permitamos.
 90 millones de iraníes sufren la mayor matanza del siglo y están aislados del mundo. ¡Sé su voz!
Eduardo Menoni (@eduardomenoni) 's Twitter Profile Photo

🚨| URGENTE: El Times revela la terrible verdad: 16.500 manifestantes muertos y 330.000 heridos en Irán 🇮🇷. Dos semanas de protestas en Irán han causado más muertes civiles que dos años de guerra en Gaza. Sin embargo, el mundo parece la otra guerra,